Atara Biotherapeutics, Inc.
ATRA
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumorsā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.81
Price-0.09%
-$0.01
1Y
Price
Market Cap
$82.942m
Small
Price/Earnings 3y Avg5y Avg
16.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+20.5%
EBITDA Margin+13.6%
Net Profit Margin-41.6%
Free Cash Flow MarginRevenue
$188.667m
+46.3%
1y CAGR+454.6%
3y CAGR+394.1%
5y CAGREarnings
$5.795m
+106.8%
1y CAGR+87.9%
3y CAGR+74.2%
5y CAGREPS
-$0.43
+96.2%
1y CAGR+54.1%
3y CAGR+50.1%
5y CAGRBook Value
-$35.041m
$36.902m
Assets$71.943m
Liabilities$15.426m
DebtDebt to Assets
41.8%
1.1x
Debt to EBITDAFree Cash Flow
-$64.006m
+7.2%
1y CAGR+33.7%
3y CAGR+20.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company